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Background/Aims: Biliary stenting is the most effective 
decompressive method for treating malignant biliary obstruc-
tive jaundice. Although the main cause of stent occlusion is 
tumor growth, few studies have investigated whether stent 
patency is affected by the combination of cancer-treatment 
modalities. The aim of this study was to evaluate the effects 
of local radiotherapy on metal-stent patency in patients 
with malignant biliary obstruction. Methods: Patients who 
underwent self-expandable biliary metallic stenting for ma-
lignant biliary obstruction from 1999 to 2007 were included. 
Forty patients received chemotherapy and radiation therapy 
(radiation group, RG), and 31 patients received only chemo-
therapy (nonradiation group, NRG). Results: The cumulative 
median stent patency was significantly longer in the RG than 
in the NRG (17.7 months; 95% confidence interval [CI], 1.8 
to 33.6 months vs 8.7 months; 95% CI, 4.9 to 12.5 months; 
p=0.025). Stent occlusion caused by tumor growth or stent 
migration occurred in two (5%) and three (7.5%) cases in 
the RG and in six (19.3%) and two (6.5%) cases in the NRG, 
respectively. Conclusions: The patency of biliary metal stents 
in pancreatobiliary cancer patients who receive chemora-
diation therapy is significantly longer than that in patients 
who do not receive radiotherapy, which suggests that local 
cancer control significantly affects stent patency. (Gut Liver 
2013;7:480-485)
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INTRODUCTION
Despite advances in therapeutic options, the 5-year survival 
rate for pancreatobiliary cancer is reported less than 5%.1 Most 
of these malignancies are inoperable at the time of diagnosis, 
and 70% to 90% of patients with pancreaticobiliary cancer have 
jaundice due to bile duct obstruction. The biliary obstruction 
exacerbates the clinical condition and quality of life by causing 
cholangitis, sepsis, and hepatic failure.2 However, the general 
condition of most patients with inoperable pancreatobiliary can-
cers is usually too poor for them to endure a major operation.2 
Biliary stenting can relieve obstructive jaundice and improve 
the quality of life for patients with inoperable pancreatobiliary 
cancer. It has also been shown to be safer and as effective as 
decompressive bypass surgery.3,4 So, biliary stent decompression 
is the preferred method of treatment. Factors influencing the 
patency of biliary metal stents include the type of metal stent 
(covered or uncovered), the various complications that occur 
as a result of stent occlusion or stent migration, and the cancer 
treatment modality used.5-11 External radiotherapy with concur-
rent chemotherapy has been treatment of choice for inoperable 
locally advanced pancreatobiliary cancer.9,10,12 Recent studies 
have also reported on the efficacy of local treatments for pan-
creatobiliary cancers consisting of external radiotherapy, intra-
luminal brachytherapy, or photodynamic treatment.12-14 Among 
these reports, studies focusing on the effects of local treatments, 
especially external radiotherapy with concurrent chemotherapy 
to the metal stent patency were relatively few.
The aim of this study was to compare the patency of biliary 
metal stents in a radiation group (RG) with a nonradiation treat-
ment group (NRG), and to determine if a local cancer treatment, 
such as radiotherapy, affects the patency of metal stents in ma-
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lignant biliary obstruction.
MATERIALS AND METHODS
1. Patients
Patients with biliary obstructions due to inoperable malignant 
causes at the Pancreatobiliary Cancer Clinic, Severance Hospital, 
Yonsei University College of Medicine, Seoul, Korea between 
January 1999 and August 2007 were included in this study. 
Forty patients with unresectable pancreatobiliary cancer who 
had been treated with concurrent chemoradiation therapy were 
assigned to the RG and 31 patients who had received only sys-
temic chemotherapy were assigned to the NRG. An inoperable 
malignant biliary obstruction was defined as an obstruction due 
to tumor at the intrahepatic or extrahepatic bile ducts that could 
not be curatively resected. In the RG, radiation therapy was ad-
ministered to the primary tumor site and regional lymph nodes. 
The total radiation dose in the RG was 45 to 50.4 grays/28 
fractions over 4 to 6 weeks by conventional radiation therapy. 
In the RG and NRG, five variable chemotherapy regimens and 
doses were used in pancreatic cancer patients as below. Gem-
citabine plus cisplatin chemotherapy (gemcitabine 1,000 mg/m2 
intravenous administration (IV) on days 1, 8, and 15; and cispl-
atin 70 mg/m2 IV on day 1 of each 4 weeks cycle), gemcitabine 
monotherapy (gemcitabine 1,000 mg/m2 IV on days 1, 8, and 15 
of each 4 weeks cycle), gemcitabine plus capecitabine combina-
tion therapy (gemcitabine 1,000 mg/m2 IV on days 1, 8, and 15; 
and oral administration of capecitabine 1,660 mg/m2 on days 1 
to days 21 of each 4 weeks cycle), 5-fluorouracil plus cisplatin 
chemotherapy (5-fluorouracil 1,000 mg/m2 IV on days 1, 2, and 
3; and cisplatin 70 mg/m2 IV on day 2 of each 4 weeks cycle), 
and taxol plus 5-fluorouracil combination therapy (taxol 175 
mg/m2 IV on day 1; and 5-fluorouracil 1,000 mg/m2 IV on days 
1, 2, and 3 of each 4 weeks cycle) were used. Furthermore, bile 
duct tract cancer patients including the ampulla of Vater cancer 
patients were treated according to the below regimens in both 
groups. Regimens of gemcitabine plus cisplatin chemotherapy 
and 5-fluorouracil plus cisplatin chemotherapy were the same 
as previously mentioned. Etoposide plus 5-fluorouracil plus ci-
platin triple combination chemotherapy (Etoposide 100 mg/m2 
IV on days 1, 2, and 3; 5-fluorouracil 1,000 mg/m2 IV on days 1, 
2, and 3; and cisplastin 70 mg/m2 IV on day 1 of each 4 weeks 
cycle), 5-fluorouracil monotherapy (5-fluorouracil 1,000 mg/m2 
IV on days 1, 2, and 3 of each 4 weeks cycle), and TS-1 mono-
therapy (oral administration of 70 mg/m2 on days 1 to days 14 
of each 3 weeks cycle) were used. This study is a restrospective 
analysis.
2. Biliary metal stent insertion
All 71 patients underwent metal stent insertion with 32 
covered and 39 uncovered stents. At first, stent insertion was 
attempted endoscopically in included patients, after confirma-
tion of unresectability and malignant biliary obstruction by 
imaging and pathologic studies. The endoscopic approach failed 
in nine cases including patients without a full expansion of 
metal stent, and then they performed by transhepatic approach 
percutaneously. A lumen diameter of metal stent just after stent 
placement and dilatation was about 10 mm in technically suc-
cessful insertion. Functional success was defined as a relieving 
of obstructive jaundice due to malignant biliary obstruction by 
metal stent insertion. All biliary metal stents were commercially 
available and manufactured by various companies (Boston Sci-
entific Co., Natick, MA, USA; Taewoong Medical Inc., Gimpo, 
Korea). Niti-S biliary covered and uncovered stent by Taewoong 
Medical Inc. were used in this study. They are made of nitinol, a 
nickel-titanium alloy with or without silicone covering. In this 
study, Wallstent bare and covered biliary stent by Boston Sci-
entific Co. were also inserted. Wallstent is manufactured from 
medical stainless steel with or without covered silicone.15
Stent malfunction was defined as a nonfunctioning stent 
status with abnormal clinical parameters showing obstructive 
jaundice, after the endoscopic or transhepatic cholangiographic 
evaluations. Causes of stent malfunction were classified as tu-
mor ingrowth, sludge impaction, extraluminal tumor compres-
sion due to cancer outgrowth, or stent migration. Stent patency 
was defined as the duration of time from stent insertion to stent 
malfunction.
 3. Evaluation
Our primary aim was to compare the patency of metal stents 
between the RG and the NRG. Our secondary aim was to de-
termine the complications and causes of stent malfunctions. 
And we also evaluated the affective factors on stent patency. 
A monthly patient follow-up was carried out according to the 
maintenance protocol of the Yonsei Pancreatobiliary Cancer 
Clinic, including laboratory test, clinical condition, and confir-
mation of stent patency.
4. Statistical analysis
Continuous variables were compared with the independent 
sample t-test and categorical variables with a chi-square test. 
Values were reported as mean±standard deviation (SD) or me-
dian with ranges. Data were expressed as median cumulative 
patency was estimated by Kaplan-Meier analysis. The associa-
tions between stent patency and risk variables were assessed by 
multivariate Cox regression analysis. Age, sex, stage of disease, 
location of the cancer (pancreatic cancer or biliary cancer), 
types of stent (covered or uncovered stent), cancer treatment 
modalities (RG or NRG), and chemotherapy regimens (gem-
citabine-based, 5-fluorouracil-based, or taxane-based drugs) 
were included as parameters in the multivariate Cox regression 
analysis. All analyses were performed by SPSS version 12.0 
(SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered 
significant.
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RESULTS
1. Patient characteristics
Seventy-one patients (44 men and 27 women) with malig-
nant biliary obstructions were included in this study. The mean 
age of the patients was 65.8±8.04 years (range, 44 to 79 years). 
There were no differences in baseline characteristics between 
patients in the RG and NRG (Table 1). In the RG, a higher pro-
portion of patients had locally advanced cancers than in the 
NRG (70% vs 22.6%, respectively; p<0.001). Pancreatic cancer 
was the most common cause of malignant biliary obstruction, 
occurring in 59% of all cases. The location of malignant tu-
mors including the pancreas, gallbladder, bile duct, or ampulla 
of Vater, was also not significantly different between the two 
groups. For patients with pancreatic cancer, the chemotherapy 
regimens included gemcitabine-based (71%), 5-fluorouracil-
based (11.9%), or taxane-based drugs (16.7%). In contrast, the 
chemotherapy regimens for cancers in the gallbladder and bile 
duct included gemcitabine (40%), a combination of 5-flouroura-
cil with cisplatin (44%), or 5-flourouracil monotherapy (16%). 
2. Stent patency
Cumulative median stent patency was significantly longer 
in the RG than in the NRG (17.7 months, 95% confidence in-
terval [CI], 1.8 to 33.6 months; and 8.7 months, 95% CI, 4.9 to 
12.5 months, respectively; p=0.025) (Fig. 1). Subgroup analysis 
revealed that the patency of covered stents (RG and NRG; 12.2 
and 7.2 months, respectively) and uncovered stents (RG and 
NRG; 17.7 and 9.6 months, respectively) was also longer in 
the RG (p=0.023). We also evaluated the prognostic factors for 
stent patency. The only influencing factor for prolonged stent 
patency was cancer treatment modality (odds ratio, 12.4; 95% 
CI, 1.1 to 141.9; p=0.042). Stent patency was only influenced by 
combined chemotherapy and radiation therapy (RG) compared 
with chemotherapy (NRG). Stent patency was not affected by 
other risk variables such as age, sex, stage, location of the can-
cer, types of stent, and regimens of chemotherapy. Regimens 
of chemotherapy were divided by following three groups; gem-
citabine-based, 5-fluorouracil-based, and taxane-based drugs. 
There was no significant difference in metal stent patency ac-
cording to each chemotherapy regimen (p=0.348).
Table 1. Patient Characteristics
Characteristic RG NRG p-value
No. of patients 40 31
Sex, M/F 25/15 (62.5/37.5) 19/12 (61.3/38.7) 0.917
Age, yr 67.2±6.9 64.0±9.0 0.094
Cancer location 0.057
   Pancreas 29 (72.5) 13 (41.9)
   Gallbladder 9 (22.5) 12 (38.7)
   Bile duct 1 (2.5) 3 (9.6)
   Ampulla of Vater 1 (2.5) 3 (9.6)
Cancer stage <0.001
   Locally advanced 28 (70.0) 7 (22.6)
   Distant metastasis 12 (30.0) 24 (77.4)
Procedure for stent insertion 0.165
   Endoscopic 37 (92.5) 25 (80.6)
   Transhepatic 3 (7.5) 6 (19.4)
Types of stent 0.810
   Covered stent 19 (47.5) 13 (41.9)
   Uncovered stent 21 (52.5) 18 (58.1)
Biochemical profiles
   AST, IU/L 133.1±128.3 123.0±98.5 0.719
   ALT, IU/L 171.6±155.7 127.3±109.3 0.182
   Alkaline phosphatase, IU/L 567.3±343.2 514.8±406.2 0.560
   Total bilirubin, mg/dL 12.3±8.5 9.8±11.3 0.280
   Bilirubin after stenting, mg/dL 2.9±3.9 2.3±2.3 0.489
Data are presented as mean±SD or number (%).
RG, radiation group; NRG, nonradiation group; M, male; F, female; AST, aspartate aminotransferase; ALT, alanine aminotransferase. 
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3. Stent complications
There were no stent insertion-related serious complications 
such as perforation or death. Stent occlusion occurred in seven 
patients (17.5%) in the RG and was caused by tumor growth 
(n=2, 5%) or sludge and foods (n=5, 12.5%). In the NRG, stent 
occlusion also occurred in seven patients (22.6%) and was 
caused by tumor growth (n=6, 19.3%) or sludge (n=1, 3.2%). 
Stent migration was observed only in covered stents with three 
cases (7.5%) in the RG and two cases (6.5%) in the NRG. There 
were no significant differences in the causes of stent malfunc-
tion between the two groups (Table 2).
DISCUSSION
This study shows that the patency of biliary metal stents in 
patients with malignant biliary obstruction receiving chemo-
radiation therapy was significantly longer than in patients 
without radiotherapy. It is suggested that local cancer control 
significantly affects stent patency.
Endoscopic stent placement using self-expandable metal 
stents (SEMS) is an established method of palliative treatment 
for relieving obstructive jaundice in patients with unresectable 
pancreatobiliary malignancies.7,16 SEMS were introduced at 
the end of the 1980s to overcome the disadvantages of plastic 
stents with respect to patency and durability.17-20 Although 
plastic stenting provides adequate drainage, late complications 
with stent occlusion from biliary infection and sludge formation 
have limited the clinical benefits of plastic stents. Therefore, 
biliary SEMS should be used if the expected survival is greater 
than 6 months.21 Factors reported to influence the patency of 
biliary stents include the type of metal stent (covered or un-
covered), the type of complication following stent occlusion, 
the presence of duodenobiliary reflux (especially for plastic 
stents),22 and the cancer treatment modality.8-11,13 Takasawa et 
al.23 reported that gemcitabine chemotherapy resulted in longer 
patency with metal stents than with plastic stents in patients 
with unresectable pancreatic cancer. Other study by Bowling et 
al.9 has shown that the number of stent changes per patient was 
not statistically different between the control group and the ra-
diotherapy group in patients with unresectable cholangiocarci-
noma. This also means that radiation treatment does not reduce 
stent changes. The authors showed that these results were due 
to longer hospitalization stays, better medical care, and more 
timely interventions for complications for patients in the radio-
therapy group, which resulted in more frequent stent changes 
than in the control group. Therefore, related studies on patients 
treated with local radiation therapy in pancreatobiliay cancers 
were focused on the survival benefit not the biliary metal stent 
Fig. 1. Median patency of metal stents in the radiation group (RG; 
solid line) and nonradiation group (NRG; dotted line). Stent patency 
in the RG was longer than that in the NRG (17.7 and 8.7 months, re-
spectively; p=0.025).
Table 2. Stent Patency and Causes of Stent Malfunction
RG (n=40) NRG (n=31) p-value
Median stent patency (95% CI), mo 17.7 (1.8-33.6) 8.7 (4.9-12.5) 0.025
    Covered 12.2 (8.7-15.7) 7.2 (6.5-7.9)
    Uncovered 17.7 (4.9-30.5) 9.6 (7.5-11.7)
Stent malfunction 10 (25.0) 9 (29.0) 0.790
    Covered stent 6 (15) 6 (19.3) 0.721
      Obstruction by tumor growth 1 (2.5) 3 (9.7)
      Sludge or cholangitis 2 (5.0) 1 (3.2)
      Stent migration 3 (7.5) 2 (6.4)
    Uncovered stent 4 (10.0) 3 (9.7) 0.539
      Obstruction by tumor growth 1 (2.5) 3 (9.7)
      Sludge or foods 3 (7.5) 0 (0)
      Stent migration 0 (0) 0 (0)
Data are presented as number (%).
RG, radiation group; NRG, nonradiation group; CI, confidence interval.
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patency.
In this study, the two treatment groups had similar clinical 
characteristics including treatment of systemic chemotherapy 
except cancer stage and location. Actually, this retrospective 
cohort study showed a mismatch of cancer stage in each group 
and heterogenous cancer types. Pancreatic cancers and biliary 
tract cancers like gallbladder cancer, intrahepatic cholangiocar-
cinoma, common bile duct cancer, or ampulla of Vater cancer 
had different tumor behavior, median overall survival and 
prognosis of disease, respectively.24-28 Especially, advanced stage 
of disease might influence stent patency caused by less active 
treatments or early death or follow-up loss. Hence, we tried to 
analyze the influencing factors on the stent patency for statisti-
cal compensating the mismatch of cancer stage and various 
types of cancer. As a result, the single factor for prolonged stent 
patency was cancer treatment modality; RG versus NRG.
This study was mainly focused on stent patency influenced 
by local control of tumors. Up to the present, a study on the ef-
fect of cancer local treatment, especially radiation therapy on 
the biliary stent patency was rarely reported. Therefore, we were 
able to demonstrate that local radiation treatment combined 
with systemic chemotherapy rather than chemotherapy alone 
can prolong the patency of biliary metal stents in unresectable 
malignant obstruction and potentially improve the quality of 
life for cancer patients with terminal stage. In subgroup analy-
sis, the overall patency of uncovered stents was similar with 
that of covered stents in both groups (RG and NRG) (p=0.14). 
The strength of this study was that it was a clinical study 
focused to the relation between active multimodality treatment, 
especially local cancer control, and the prolongation of metal 
stent patency in advanced cancer patients with poor prognosis. 
Consequently, this prolongation could cause the improvement 
of quality of life in terminally ill patients. However, our study 
had some limitations. It was not a large-scale, randomized, 
prospective study, even though the follow-up protocol was pre-
defined. There would be a selection bias due to nonrandomized 
controlled trial. Additionally, there were significant differences 
in cancer stages between the two groups, in spite of statistical 
adjustment on the effects of stent patency. And, heterogenous 
cancer types, especially small number of cases with a part of 
biliary tract cancers, were one of the difficult factors to analyze. 
Placement of not unified stents from various manufacturers’ 
covered or uncovered stent were also an obstacle to perform 
a precise analysis. Although the minimal tendency to have a 
better survival was showed in the RG, median overall survival 
days were not significantly different between two groups in this 
study (p=0.906). Subgroup analysis dividing disease stage (lo-
cally advanced versus distant metastasis) in patients with pan-
creatic cancer had similar findings without statistical difference.
In conclusion, the patency of metal stents was significantly 
prolonged in the RG compared to the NRG. Therefore, the pa-
tency of stents can be prolonged by local cancer treatment in 
unresectable malignant biliary obstruction. Comparisons of stent 
patency should be interpreted carefully with consideration of 
treatment modalities. Future prospective studies involving larger 
numbers of patients are required to further elucidate the effects 
of local treatment of pancreatobiliary cancer on the improve-
ment of metal stent patency.
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